Edition:
United Kingdom

People: Infant Bacterial Therapeutics AB (IBTb.ST)

IBTb.ST on Stockholm Stock Exchange

215.00SEK
5:00pm BST
Change (% chg)

-2.00kr (-0.92%)
Prev Close
217.00kr
Open
214.50kr
Day's High
225.00kr
Day's Low
210.00kr
Volume
5,094
Avg. Vol
13,490
52-wk High
274.50kr
52-wk Low
115.00kr

Connolly, Eamonn 

Mr. Eamonn Connolly, Ph.D. serves as Head of Research & Development at Infant Bacterial Therapeutics AB. Eamonn is the former VP Research of BioGaia, with 15 years experience working with pre-clinical and clinical research on live bacterial therapies. He has earlier experience from the pharmaceutical industry including leading positions in R&D at Kabi Vitrum, Pharmacia & Upjohn and Fresenius Kabi.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --